DE69433996D1 - Verwendung pharmazeutischer zusammensetzungen zur behandlung von neurodegenerativen krankheiten - Google Patents

Verwendung pharmazeutischer zusammensetzungen zur behandlung von neurodegenerativen krankheiten

Info

Publication number
DE69433996D1
DE69433996D1 DE69433996T DE69433996T DE69433996D1 DE 69433996 D1 DE69433996 D1 DE 69433996D1 DE 69433996 T DE69433996 T DE 69433996T DE 69433996 T DE69433996 T DE 69433996T DE 69433996 D1 DE69433996 D1 DE 69433996D1
Authority
DE
Germany
Prior art keywords
treatment
pharmaceutical compositions
neurodegenerative diseases
new
interaction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69433996T
Other languages
English (en)
Other versions
DE69433996T2 (de
Inventor
Jacques Mallet
Frederic Revah
Jean-Jacques Robert
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharma SA
Original Assignee
Aventis Pharma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma SA filed Critical Aventis Pharma SA
Application granted granted Critical
Publication of DE69433996D1 publication Critical patent/DE69433996D1/de
Publication of DE69433996T2 publication Critical patent/DE69433996T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/13—Decoys
DE69433996T 1993-06-30 1994-06-27 Verwendung pharmazeutischer zusammensetzungen zur behandlung von neurodegenerativen krankheiten Expired - Lifetime DE69433996T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9307962A FR2707880B1 (fr) 1993-06-30 1993-06-30 Compositions pharmaceutiques et leur utilisation, notamment pour le traitement des maladies neurodégénératives.
FR9307962 1993-06-30
PCT/FR1994/000771 WO1995001429A1 (fr) 1993-06-30 1994-06-27 Compositions pharmaceutiques et leur utilisation, notamment pour le traitement des maladies neurodegeneratives

Publications (2)

Publication Number Publication Date
DE69433996D1 true DE69433996D1 (de) 2004-10-21
DE69433996T2 DE69433996T2 (de) 2005-09-22

Family

ID=9448720

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69433996T Expired - Lifetime DE69433996T2 (de) 1993-06-30 1994-06-27 Verwendung pharmazeutischer zusammensetzungen zur behandlung von neurodegenerativen krankheiten

Country Status (15)

Country Link
US (1) US6140112A (de)
EP (2) EP1454984A1 (de)
JP (1) JP3755825B2 (de)
KR (1) KR100517879B1 (de)
AT (1) ATE276360T1 (de)
AU (1) AU696644B2 (de)
CA (1) CA2166318C (de)
DE (1) DE69433996T2 (de)
DK (1) DK0707644T3 (de)
ES (1) ES2227528T3 (de)
FI (1) FI120942B (de)
FR (1) FR2707880B1 (de)
NO (1) NO321455B1 (de)
PT (1) PT707644E (de)
WO (1) WO1995001429A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6017903A (en) 1996-09-27 2000-01-25 Guilford Pharmaceuticals Inc. Pharmaceutical compositions and methods of treating a glutamate abnormality and effecting a neuronal activity in an animal using NAALADase inhibitors
US5824662A (en) 1996-09-27 1998-10-20 Guilford Pharmaceuticals Inc. Treatment of global and focal ischemia using naaladase inhibitors
JP2002514184A (ja) 1996-09-27 2002-05-14 ギルフォード ファーマスーティカルズ インコーポレイテッド Ｎａａｌａｄアーゼ組成物ならびに動物におけるグルタメート異常を治療する方法および神経活性をもたらす方法
CA2300328A1 (en) 1999-09-14 2001-03-14 Cardiogene Gentherap. Systeme Ag Modulating transcription of genes in vascular cells
CN1315402A (zh) * 2000-03-28 2001-10-03 上海博德基因开发有限公司 一种新的多肽——人淀粉类前体蛋白结合蛋白14和编码这种多肽的多核苷酸
CN1315439A (zh) * 2000-03-29 2001-10-03 上海博德基因开发有限公司 一种新的多肽——人淀粉类前体蛋白结合蛋白9和编码这种多肽的多核苷酸
DE10308045B3 (de) 2003-02-26 2004-06-17 Lurgi Ag Verfahren und Vorrichtung zur kontinuierlichen Gewinnung freier Weinsäure aus Kaliumhydrogentartrat enthaltenden Rohstoffen

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2573436B1 (fr) * 1984-11-20 1989-02-17 Pasteur Institut Adn recombinant comportant une sequence nucleotidique codant pour un polypeptide determine sous le controle d'un promoteur d'adenovirus, vecteurs contenant cet adn recombinant, cellules eucaryotes transformees par cet adn recombinant, produits d'excretion de ces cellules transformees et leurs applications, notamment a la constitution de vaccins
WO1991011535A1 (en) * 1990-01-30 1991-08-08 Childrens Hospital Of Los Angeles Inhibition of transcription by double-stranded oligonucleotides
WO1991018088A1 (en) * 1990-05-23 1991-11-28 The United States Of America, Represented By The Secretary, United States Department Of Commerce Adeno-associated virus (aav)-based eucaryotic vectors
FR2675803B1 (fr) * 1991-04-25 1996-09-06 Genset Sa Oligonucleotides fermes, antisens et sens et leurs applications.
GB9114437D0 (en) * 1991-07-03 1991-08-21 Health Lab Service Board Recombinant adenoviruses and the use thereof for detecting the presence in eukaryotic cells of the expression products of specific genes
FR2708283B1 (fr) * 1994-01-14 1995-10-20 Rhone Poulenc Rorer Sa Compositions pharmaceutiques et leur utilisation, notamment pour le traitement des maladies neurodégénératives.

Also Published As

Publication number Publication date
CA2166318C (fr) 2009-02-10
ATE276360T1 (de) 2004-10-15
DE69433996T2 (de) 2005-09-22
CA2166318A1 (fr) 1995-01-12
AU696644B2 (en) 1998-09-17
NO954888D0 (no) 1995-12-01
FI120942B (fi) 2010-05-14
KR960703432A (ko) 1996-08-17
JP3755825B2 (ja) 2006-03-15
NO954888L (no) 1995-12-01
EP0707644A1 (de) 1996-04-24
KR100517879B1 (ko) 2005-12-16
AU7188294A (en) 1995-01-24
US6140112A (en) 2000-10-31
EP0707644B1 (de) 2004-09-15
NO321455B1 (no) 2006-05-15
FR2707880B1 (fr) 1995-10-06
ES2227528T3 (es) 2005-04-01
WO1995001429A1 (fr) 1995-01-12
PT707644E (pt) 2005-01-31
DK0707644T3 (da) 2005-01-17
FI956353A0 (fi) 1995-12-29
FI956353A (fi) 1995-12-29
FR2707880A1 (fr) 1995-01-27
EP1454984A1 (de) 2004-09-08
JPH08512043A (ja) 1996-12-17

Similar Documents

Publication Publication Date Title
ES2160707T3 (es) Composiciones que comprenden agentes deteriorantes del adn y p53.
DE69230789D1 (de) Methoden zur behandlung von durch den tumor nekrose faktor ausgelösten krankheiten
ATE231549T1 (de) Verfahren zur konservierung von infektiösen rekombinierenden viren, virale wässrige suspension und ihre medizinische verwendung
ATE486614T1 (de) Zusammensetzungen zum einsatz in einer gentherapie zur behandlung von hämophilie
RU95115239A (ru) Аналог эритропоэтина
DE69230046D1 (de) 2-Bromomelatonin zur Behandlung von Schlafstörungen
DE69233760D1 (de) Inhibitoren der menschlichen Elastase von Neutrophilen
ATE294854T1 (de) Gewebespezifische und ziel-rna-spezifische ribozyme
ATE228016T1 (de) Lebendvakzine zur behandlung von tumorerkrankungen
DE69433996D1 (de) Verwendung pharmazeutischer zusammensetzungen zur behandlung von neurodegenerativen krankheiten
DE68912155T2 (de) Antivirales Kombinationspräparat.
ATE180277T1 (de) Zur behandlung von tumoren und hiv-infektionen nützliches pflanzliches protein
NO945031D0 (no) Anvendelse av en hymenopteragift til fremstilling av et medikament for behandling av DNA-virusinfeksjoner
FI961494A0 (fi) Farmaseuttisia koostumuksia ja niiden käyttö, etenkin hermoston rappeutumissairauksien hoitamiseksi
ATE69949T1 (de) Liposomen mit inhalativen allergenen zur behandlung von allergien, verfahren zu ihrer herstellung und diese enthaltende arzneimittel.
DE69231465D1 (de) Methode und zusammensetzung zur behandlung von herpes ähnlichen krankheiten
ATE65543T1 (de) Dna-sequenzen des ebv-genoms, rekombinante dnamolek¨le, verfahren zur herstellung von ebvverwandten antigenen sowie diagnostische zusammensetzungen und pharmazeutische zusammensetzungen, die die genannten antigene enthalten.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8328 Change in the person/name/address of the agent

Representative=s name: PFENNING MEINIG & PARTNER GBR, 80339 MUENCHEN

8328 Change in the person/name/address of the agent

Representative=s name: MAIWALD PATENTANWALTSGESELLSCHAFT MBH, 80335 MUENC